| |
|
|
| |
EVENT DETAILS |
<P><SPAN STYLE="font-family: georgia, palatino; font-size: small;"><STRONG>Title:</STRONG>Sequencing the Cancer Genome</SPAN></P>
<P><SPAN STYLE="font-family: georgia, palatino; font-size: small;"> The application of massively parallel sequencing to decoding cancer genomes in comparison to matched normal tissue genomes has occurred over the past seven years. Our group published the first such description in 2008 and subsequent efforts have profiled the mutational landscape of thousands of cancer genomes. In these studies, several truths have emerged. For example, we know there are shared frequently mutated genes across multiple tissue sites affected by cancer. Unexpected genes that drive cancer's development also have been uncovered such as metabolic genes (IDH1/2, TET2), spliceosome genes (SF3B1 and others), and histone reader/writer genes (EZH2, AXL, etc.). In spite of the wealth of knowledge gained from these efforts, many questions remain about the functional impact of mutated genes on cancer's development, the drugs that might target these mutated proteins, and the other aspects of cancer development and treatment. My lecture will focus on the lessons learned from genomics and the newest clinical translational aspects of cancer genomics.</SPAN></P>
<P><SPAN STYLE="font-family: georgia, palatino; font-size: small;"><STRONG>Speaker Biography:</STRONG><SPAN STYLE="line-height: 18.399999618530273px;">Dr. Elaine Mardis graduated Phi Beta Kappa from the University of Oklahoma with a B.S. degree in zoology. She then completed her Ph.D. in Chemistry and Biochemistry in 1989, also at Oklahoma. Following graduation,</SPAN><SPAN STYLE="line-height: 18.399999618530273px;">Dr. Mardis was a senior research scientist for four years at BioRad Laboratories in Hercules, CA.</SPAN></SPAN></P>
<P STYLE="text-align: justify;"><SPAN STYLE="font-family: georgia, palatino; font-size: small;"><SPAN STYLE="line-height: 18.399999618530273px;">In 1993, Dr. Mardis joined The Genome Institute at Washington University School of Medicine. As Director of Technology Development, she helped create methods and automation pipelines for sequencing the Human Genome.</SPAN></SPAN></P>
<P STYLE="line-height: 14.949999809265137px; text-align: justify;"><SPAN STYLE="font-family: georgia, palatino; font-size: small;"><SPAN STYLE="line-height: 18.399999618530273px;">Dr. Mardis has research interests in the application of next-generation sequencing to characterize cancer genomes and transcriptomes, and using these data to support therapeutic decision-making. She also is interested in facilitating the translation of basic science discoveries about human disease into the clinical setting.</SPAN></SPAN></P>
<P STYLE="line-height: 14.949999809265137px; text-align: justify;"><SPAN STYLE="font-family: georgia, palatino; font-size: small;"><SPAN STYLE="line-height: 18.399999618530273px;">Dr. Mardis serves as an editorial board member of</SPAN>Molecular Cancer Research<SPAN STYLE="line-height: 18.399999618530273px;">,</SPAN>Disease Models and Mechanisms<SPAN STYLE="line-height: 18.399999618530273px;">and</SPAN>Annals of Oncology,<SPAN STYLE="line-height: 18.399999618530273px;">and acts as a reviewer for</SPAN>Nature, the New England Journal of Medicine, Cell<SPAN STYLE="line-height: 18.399999618530273px;">and</SPAN>Genome Research<SPAN STYLE="line-height: 18.399999618530273px;">.</SPAN><SPAN STYLE="line-height: 18.399999618530273px;">She serves on the scientific advisory boards of Qiagen Ingenuity, DNA Nexus, and ZS Genetics. Dr. Mardis received the Scripps Translational Research award for her work on cancer genomics in 2010, and was named a Distinguished Alumni of the University of Oklahoma College of Arts and Sciences for 2011. Discover Magazine featured her work in cancer genomics as one of their top 100 science stories in 2013.</SPAN></SPAN></P>
|
|
|
|
|
|
